SG&A Efficiency Analysis: Comparing Blueprint Medicines Corporation and Apellis Pharmaceuticals, Inc.

Biotech SG&A: Apellis vs. Blueprint's Expense Strategies

__timestampApellis Pharmaceuticals, Inc.Blueprint Medicines Corporation
Wednesday, January 1, 201429081667890000
Thursday, January 1, 2015635678214456000
Friday, January 1, 2016430374319218000
Sunday, January 1, 20171046315127986000
Monday, January 1, 20182263918447928000
Tuesday, January 1, 20196704648396388000
Wednesday, January 1, 2020139401000157743000
Friday, January 1, 2021176771000195293000
Saturday, January 1, 2022277163000237374000
Sunday, January 1, 2023500815000295141000
Monday, January 1, 2024359272000
Loading chart...

Data in motion

SG&A Efficiency: A Tale of Two Biotechs

In the competitive world of biotechnology, managing operational expenses is crucial for success. Over the past decade, Apellis Pharmaceuticals, Inc. and Blueprint Medicines Corporation have demonstrated contrasting strategies in their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Apellis Pharmaceuticals saw a staggering increase in SG&A expenses, growing from approximately $2.9 million to over $500 million, marking a growth of over 17,000%. In contrast, Blueprint Medicines started with higher initial expenses of around $7.9 million in 2014, reaching nearly $295 million by 2023, a growth of about 3,600%.

This divergence highlights Apellis's aggressive expansion strategy, while Blueprint's steadier growth suggests a more measured approach. Investors and industry analysts can glean insights into each company's operational focus and strategic priorities by examining these trends.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025